African trypanosomiasis (sleeping sickness) is a parasitic infection that is fatal if not treated. The incidence of disease is rising, there are no vaccines, and current therapy is inadequate. This is an ongoing project to study DNA topoisomerases as potential targets for rational new antitrypanosomal drug therapy. The topoisomerases are enzymes essential for the orderly synthesis of nucleic acids and for cell survival, furthermore, they are proven targets for a variety of clinically important antibacterial and antitumor drugs. Previous work from this laboratory has shown that potent and specific inhibitors yield valuable insights into the normal function of topoisomerases in trypanosomes and that the severity of the resulting lesions correlates with cytotoxicity. Recent studies have revealed that trypanosomes have a highly unusual topoisomerase I gene that lacks the expected active site motif.
The specific aims of the proposed work are three: First is to study topoisomerase I: characterize the enzyme itself (identify the active site residue, obtain an x-ray crystal structure) and define the metabolic consequences of topo I inhibition.
The second aim i s to continue studies of topoisomerase II by isolating a nuclear enzyme and evaluating the effects of topo II inhibitors on nuclear DNA metabolism. The third goal is to bring these molecular studies closer to the clinic by assessing the structure-activity relationship of topoisomerase inhibitors, seeking compounds that are selectively toxic for parasites, compared with mammalian cells. Inhibitors that appear most promising will be evaluated in mice. This work will increase our understanding of these critical enzymes in trypanosomal metabolism, and it offers some hope for the development of much-needed new therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI028855-09
Application #
2886631
Study Section
Tropical Medicine and Parasitology Study Section (TMP)
Program Officer
Gottlieb, Michael
Project Start
1990-08-01
Project End
2003-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Nenortas, Nathaniel P; Cinelli, Maris A; Morrell, Andrew E et al. (2018) Activity of Aromathecins against African Trypanosomes. Antimicrob Agents Chemother 62:
Meyer, Kirsten J; Shapiro, Theresa A (2013) Potent antitrypanosomal activities of heat shock protein 90 inhibitors in vitro and in vivo. J Infect Dis 208:489-99
Roy Chowdhury, Arnab; Bakshi, Rahul; Wang, Jianyang et al. (2010) The killing of African trypanosomes by ethidium bromide. PLoS Pathog 6:e1001226
Tang, Sonya C; Shapiro, Theresa A (2010) Newly identified antibacterial compounds are topoisomerase poisons in African trypanosomes. Antimicrob Agents Chemother 54:620-6
Bakshi, Rahul P; Sang, Dongpei; Morrell, Andrew et al. (2009) Activity of indenoisoquinolines against African trypanosomes. Antimicrob Agents Chemother 53:123-8
Scocca, Jane R; Shapiro, Theresa A (2008) A mitochondrial topoisomerase IA essential for late theta structure resolution in African trypanosomes. Mol Microbiol 67:820-9
Kulikowicz, Tomasz; Shapiro, Theresa A (2006) Distinct genes encode type II Topoisomerases for the nucleus and mitochondrion in the protozoan parasite Trypanosoma brucei. J Biol Chem 281:3048-56
Bakshi, Rahul P; Shapiro, Theresa A (2004) RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential. Mol Biochem Parasitol 136:249-55
Nenortas, Elizabeth; Kulikowicz, Tomasz; Burri, Christian et al. (2003) Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions. Antimicrob Agents Chemother 47:3015-7
Bodley, Annette L; Chakraborty, Asit K; Xie, Suji et al. (2003) An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci U S A 100:7539-44

Showing the most recent 10 out of 31 publications